The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects

Summary

A two-part study for NAFLD subjects with normal liver functions and in general good health to be treated with CM-101 or matching placebo and NAFLD/NASH Activity Score (NAS) \< 3 that are in general good health and have normal liver functions to be treated with CM-101.

Timeline

Start

2018-12-11

Primary completion

2020-04-27

Completion

2020-04-27

Publications

• Mor A, Friedman S, Hashmueli S, Peled A, Pinzani M, Frankel M, Safadi R. Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies. Drug Saf. 2024 Sep;47(9):869-881. doi: 10.1007/s40264-024-01436-2. Epub 2024 Jun 1.

Drugs

Indications